PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiCommercial · Prior Auth · Medical Policy · DermatologyMedium impact

Hidradenitis Suppurativa (HS)

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

Prior authorization is required for hidradenitis suppurativa (HS) treatment with Cosentyx (secukinumab), Hadlima (adalimumab-bwwd) and Simlandi (adalimumab-ryvk). Hadlima and Simlandi are the adalimumab formulary options effective 01/01/2025. Abrilada, Amjevita, Bimzelx (bimekizumab-bkzx), Cyltezo, Hulio, Humira, Hyrimoz, Idacio, Yuflyma and Yusimry are not covered on any BCBSMS Formulary. The 10/21/2026 policy history entry removed the documented Hurley Stage requirement and the documented intolerance, contraindication or hypersensitivity requirement from the initial criteria, and removed the documented clinical improvement requirement from the renewal criteria.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 7 steps
01Billing team: Get prior authorization for Cosentyx (secukinumab), Hadlima (adalimumab-bwwd) or Simlandi (adalimumab-ryvk).
02Confirm the prescriber is a board certified dermatologist or has consulted with a board certified dermatologist.
03Confirm the individual is not currently being treated with another immunomodulatory agent such as a TNF-inhibitor, JAK inhibitor or IL-inhibitor.
04Confirm the prescribed dosage is within the program quantity limits based on FDA approved labeled dosage.
05Samples do not count as current or stable therapy.
06Services related to delivery and/or administration of a medication that were not approved through the BCBSMS PA review process will be considered not medically necessary.
07Approvals last 12 months.

Codes mentioned

L73.2J0135J0139Q5131Q5132Q5140Q5141Q5142Q5143Q5144Q5145

Original notice

Hidradenitis Suppurativa (HS)
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account